spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

Symposium on Digitalization and Big Data in Biotech and Pharma

Datahow_Symposium_2018

6 June 2018
ETH Zurich, Institute for Chemical and Bioengineering, Vladimir-Prelog-Weg 1

The Symposium on Digitalization and Big Data in Biotech & Pharma will bring together experts and key stakeholders from industry and academia to discuss and current digital innovations and technological trends in the pharmaceutical sector. The presentations by leading industry experts and technology pioneers are complemented by interactive round table discussions, a netwroking lunch, as well as poster and product solution exhibition. The event is organized by the group of Prof. Morbidelli from the Institute of Chemical and Bioengineering at ETH Zurich, Switzerland, and takes place at the Hönggerberg campus of ETH Zurich.

Aim

The symposium brings together key stakeholders and experts in the interdisciplinary field of technology digitalization in the biotechnological and pharmaceutical sectors. All presentations will be based on industrial case studies. Several characteristic perspectives will addressed such as digital needs in R&D and manufacturing, data storage and cloud solutions, centralization and standardization, automated solutions, added value and knowledge generation, on-site integration and transfer as well as regulatory aspects. The symposium aims to outline the key conceptual and implementation challenges, and to highlight the potential of the tools and approaches, which have already been developed and installed. Given the high levels and diversity of the speakers a list of central business and technology drivers will be worked out, which will be later on available as a white paper.

Key Topics

· Role of big data in the pharmaceutical and healthcare business model

· Technological possibilities and limitations for pharmaceutical process digitalization

· Potential of quantitative tools and models

· Available technology, expertise and solutions

· Regulatory agency perspective

· Successful industrial implementations and outlook

Further information and registration

Please visit https://www.datahow.ch/events or contact bigdata@chem.ethz.ch

email bigdata@chem.ethz.ch
web bit.ly/2Fkd10Q
email ETH Zurich, Institute for Chemical and Bioengineering, Vladimir-Prelog-Weg 1
 
Print this page
Send to a friend
   
spacer
Industry Events

DIA 2018 Global Annual Meeting

24-28 June 2018, Boston, MA

The DIA 2018 Global Annual Meeting brings together thousands of innovators from around the globe. Designed to drive insights into action by connecting key policy discussions to real-world knowledge that you need to do your job every day, your attendance will accelerate your growth and your organization's performance in the development ecosystem.
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>


News and Press Releases

Phenomenex Introduces bioZen Series for Characterization of Biotherapeutics

Torrance, Calif. (April 16, 2018) – Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, introduces bioZen – a new series of LC solutions for bioseparations in pharmaceutical, biopharmaceutical and academic research. The series encompasses both proven and entirely new media spanning two particle platforms – core-shell and thermally modified fully porous – along with new biocompatible titanium hardware. The initial bioZen product line features seven chemistries for the UHPLC and HPLC characterization of biotherapeutics such as monoclonal antibodies, antibody-drug conjugates and biosimilars. The offering includes specific LC chemistries for the analysis of aggregates and total mAb, intact mass and fragments, peptide mapping and quantitation and glycan mapping.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement